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Introduction
 Cancer-associated muscle weakness represents a re-
search challenge and a serious clinical problem. In fact, there 
is an 80% of mortality and an increased toxicity from cancer 
treatment[1-3]. The reason behind the problem of skeletal mus-
cle weakness on advanced cancer patients relays on the fact that 
they also often have bone metastases and associated bone pain, 
fractures, hypercalcemia and nerve compression syndromes[4]. 
As a consequence, in the setting of bone fragility, muscle weak-
ness is likely to increase the fracture risk even more than bone 
metastasis on its own. 
Bone Metastases
 Cancer metastasizes by completing a series of events 
known as the metastatic cascade. Tumor cells detach from the 
primary site, invade the adjacent extracellular matrix, enter the 
circulation through a process known as intravasation. Once at 
the target organ, tumor cells extravasate into the parenchyma to 
establish micro metastases, and the final outgrowth and coloni-
zation at the distant target. Circulating tumor cells from certain 
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Mechanisms of Muscle Weakness Associated with Bone 
Metastases
Abstract
 Cancer-associated muscle dysfunction represents a deadly clinical problem, 
with ca. 80% mortality together with an increased toxicity from cancer treatment. 
. The normal bone remodeling might be disrupted by tumor cells that metastasize 
to bone in certain stages of cancer, which results in increased morbidity including 
muscle weakness. The reason for that muscle weakness might be attributed to the 
reduction on muscle mass or the reduction of muscle function. In fact, it has been 
demonstrated that in advanced cancers, it is probably caused by a combination of 
reductions, quantity and quality of muscle. This review focuses on the mechanisms 
that bone metastases promote skeletal muscle weakness
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types of cancer like breast and prostate have particular affinity 
to grow in bone. The bone microenvironment is a fertile soil for 
tumor growth as it houses abundant growth factors which act on 
tumors to fuel growth and other invasive behavior.
 Bone is a dynamic organ and its homeostasis is main-
tained by a balanced production of osteoblast and osteoclasts. 
The relationship between osteoblastic bone formation and os-
teoclastic bone resorption is balanced in healthy individuals. In 
various bone diseases including malignancy, disruption of this 
balance result in loss of the normal structural integrity of the 
skeleton[5]. Tumor cells excessively stimulate osteoclasts and 
osteoblasts, an interaction that is critical for tumor cell survival 
(Figure 1). 
 Patients with bone metastases have significant morbid-
ity, including bone pain, fracture, hypercalcemia, muscle weak-
ness and spinal cord compression. Cancer patients, who develop 
bone metastases, can survive for many years, during which they 
will suffer significant comorbidity; but once cancer metastasizes 
to bone the tumor is incurable. These comorbidities are known 
collectively as skeletal-related events (SREs). SREs are associ-
ated with impaired mobility, reduced quality of life[6], increased 
2mortality, and higher healthcare costs. Standard antiresorptive 
treatments, such as zoledronic acid or denosumab, decrease 
skeletal morbidity and delays SRE, but do not cause regression 
or cure the disease[4-7].
Figure 1:  H&E stained sections from mouse with breast cancer bone 
metastases showing bone resorbing osteoclasts (white arrow) and bone 
forming Osteoblasts (black arrows). Both cells are interacting with tu-
mor cells (T).
 Bone metastases are classified according to the radio-
graphic appearance into osteolytic or osteoblastic lesions. How-
ever, most bone metastases have components of osteolytic and 
osteoblastic activity. Certain types of cancer cause predominant-
ly osteolytic lesion such as breast cancer while other cancers 
cause predominantly osteoblastic lesions like prostate cancer.
TGF-β and bone metastases
 The bone microenvironment is unique and may provide 
a fertile soil for cancer to thrive. The normal homeostasis be-
tween bone cells is disrupted by the release of growth factors 
and cytokines as a result of the presence of tumor cells within the 
bone microenvironment. The growth factors and cytokines are 
embedded in the mineralized bone matrix. Transforming growth 
factor-β (TGF-β) is the most abundant of these factors. TGF-β is 
part of a large family of polypeptide growth factors that includes 
activins, inhibins, and bone morphogenetic proteins (BMPs).
TGF-β is released in a latent form and it is the proteolytic cleav-
age, interaction with integrins, or pH changes in the local en-
vironment that activates TGF-β. High local levels of liberated 
TGF-β result in increased tumor invasion, angiogenesis as well 
as immune suppression. In addition, TGF-β stimulates tumor 
production of osteolytic factors that stimulate further bone re-
sorption[8,9]. This categorizes TGF-β as a crucial factor responsi-
ble for driving the feed-forward vicious cycle of tumor growth in 
bone. Therefore blocking TGF-β release, its production and/or 
signaling is a promising strategy to treat bone metastasis. Over 
the past two decades, several therapeutic strategies have been 
developed to inhibit TGF-β including TGF-β receptor I kinase 
inhibitors, TGF-β neutralizing antibodies, soluble receptor de-
coy-Fc fusions and TGF-β antisense oligonucleotides[10].
Muscle weakness and cachexia in cancer patients
 Muscle weakness and fatigue is a significant co-mor-
bidity of osteolytic bone metastases. This is often associated 
with cancer cachexia; a paraneoplastic syndrome associated 
with many types of cancer and is characterized by severe wast-
ing due to loss of lean and fat mass[11]. Cachexia has long been 
recognized as a syndrome with an independent adverse effect on 
patients with cancer. Once cachexia has progressed to a clinical-
ly evident refractory stage, it is generally considered irreversible 
and is associated with an extremely high mortality[12,13]. Cancer 
cachexia is associated with high levels of interleukin (IL)-6, 
which is regulated by HIF-1α, NFκ B and TGF-β[11]. However, 
there are no effective therapies for muscle weakness or cachexia. 
Current clinical trials focus on improvement of muscle mass, but 
muscle function per se has not been adequately studied.
Normal muscle contraction and role of RYR2 in muscle 
function
 Excitation-contraction coupling is the process by which 
an electrical impulse of muscle fibers initiates muscle contrac-
tion. It is the activation of Ach nicotinic receptors that induces 
an end-plate potential and this electrical impulse continues along 
the muscle fiber as an action potential[14]. The action potential 
depolarization is generated primarily by current through Nav1.4 
sodium channels, the skeletal muscle voltage-gated sodium 
channel, localized at the sarcolemma and through the transverse 
(T)-Tubule system of the myofiber. Depolarization of the T-tu-
bule membrane induces conformational changes in the T-tubule 
EC coupling voltage sensor, the voltage-gated Ca2+ channel, 
also known as the dihydropyridine receptor (DHPR). In skeletal 
muscle, the DHPR is mechanically coupled to the ryanodine re-
ceptor Ca2+ release channel type 1(RyR1), which in contrast to 
the DHPR, rests in the sarcoplasmic reticulum[14].
 Ryanodine receptors (RyRs) are intracellular Ca2+ 
release channels on the sarcoplasmic and endoplasmic reticu-
la required for fundamental cellular functions in most tissues, 
including skeletal and cardiac muscle excitation–contraction 
coupling, synaptic transmission and pancreatic beta cell func-
tion[15]. It is a Ca2+ permeable non-selective cation channel that 
releases Ca2+ stored in the sarco-endoplasmic reticulum of excit-
able and non-excitable cells. This ion channel is a tetramer and 
each sub unit contains approximately 5000aa, so one single ion 
channel weights around 2MDa[16]. The type 1 Ryanodine Recep-
tor (RyR1) mediates excitation–contraction coupling in skeletal 
muscle. Approximately 50% of RyR1 channels are mechanically 
activated by direct interaction with voltage-gated Ca2+ channels 
(VGCCs) on the plasma membrane[15]. Pathological oxidation of 
RyR1 results in leaky channels that contribute to muscle weak-
ness[17,18].
Oxidative stress and Cancer    
 Oxidative stress is one of the most important events 
that gives rise to the conditions leading to tumor onset and pro-
gression[19]. Reactive oxygen species (ROS) is one of the most 
important species of free radicals. It is produced by various met-
abolic pathways, including mitochondrial aerobic metabolism. 
It plays a critical role in the initiation and progression of various 
types of cancers. ROS controls many cellular processes, includ-
ing cell proliferation, and thus stimulates the uncontrolled cell 
growth which may lead to tumor development[20]. 
 In the case of chronic inflammation, the secretion of 
reactive oxygen/nitrogen species (ROS/RNS) might lead to the 
amplification of dysregulated processes and eventually to a de-
Int J Cancer Oncol     |     Volume 4: Issue 1www.ommegaonline.org
Bone Metastases
velopment of preneoplastic condition. If the amount of cellular 
ROS/RNS produced is high enough to overcome endogenous 
antioxidant response, an irreversible oxidative damage to nucle-
ic acids, lipids, and proteins may cause genetic and/or epigenetic 
alterations leading to the dysregulation of oncogenes and tumor 
suppressor genes. Hence, the oxidative stress and chronic in-
flammation processes are tightly coupled and the failure to block 
these processes could result in genetic/epigenetic changes that 
drive the initiation of carcinogenesis[21]. Low antioxidant status 
and increased oxidative stress levels are detected in cancer pa-
tients, even before oncology treatment starts. Hence the evalu-
ation of tissue redox status has a diagnostic potential in oncolo-
gy[22].
Muscle weakness and RYR1 oxidation in bone metastases
 To study the role of oxidation in muscle weakness asso-
ciated with osteolytic bone metastases, we examined mice with 
bone metastases resulting from different human cancers, includ-
ing breast cancer (MDA-MB-231, MCF-7and, ZR-75-1), lung 
cancer (A549 and RWGT2), prostate cancer (PC-3) and multiple 
myeloma (JJN3). We compared the results obtained from each 
group of mice with those from non-tumor bearing mice. The tu-
mor-bearing mice developed muscle weakness when compared 
to the non-tumor control mice. This is presented as a reduction in 
forelimb grip strength and the Extensor Digitorumlongus (EDL) 
muscle showed lower ex vivo muscle-specific force. We tested 
for peak tetanic Ca2+ to determine muscle force, and we found 
that this was also lower in the MDA-MB-231–inoculated mice 
than in the non–tumor-bearing control mice. Thus, in addition to 
loss of muscle mass, mice with breast cancer bone metastases 
had loss of muscle function[23]. This observation was extended 
in murine models of several other cancer that caused osteolytic 
lesion including lung cancer, prostate cancer and multiple my-
eloma as well as in murine models with osteoblastic bone metas-
tases including the ZR-75-1 and MCF-7 breast cancer model.
 Since our data indicate that muscle weakness strongly 
correlated with bone destruction and remodeling, we further in-
vestigated whether the interaction between tumor-bone micro-
environment plays a role in cancer-associated muscle weakness. 
Using a mammary fat pad breast cancer mouse model, we in-
oculated breast cancer cell MDA-MB-231 cells (106) into the 
mammary fat pad. In this model tumor grow locally and do not 
metastasize to the bone. We found that, in contrast to mice with 
bone metastases, mice with primary MDA-MB-231 mammary 
tumors had normal muscle function. These mice had no differ-
ence in body weight, body composition or muscle mass, com-
pared to non-tumor bearing controls. Notably, these mice did 
not exhibit the biochemical signature of leaky RyR1 channels, 
in contrast to mice with bone metastases. These data suggest that 
the invasion of the bone-microenvironment with tumor cells has 
a critical role in the development of cancer-associated muscle 
weakness.
 Skeletal muscle from mice and humans with bone 
metastases exhibited higher skeletal muscle protein oxidation 
as compared to muscle from mice and humans without bone 
metastases. These included sarcomeric proteins (tropomyosin 
and myosin and others) and the RyR1 Ca2+ release channel, 
which was identified as being both nitrosylated and oxidized. 
Our data indicated that, oxidation of RyR1 channels in skeletal 
muscle results in a pathological SR Ca2+ leak that is associated 
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with muscle weakness in the mouse model of bone metastases. 
Skeletal muscle RyR1 channels from mice with bone metasta-
ses were oxidized, nitrosylated and depleted of the stabilizing 
subunit calstabin1 (also known as FKBP12) when compared 
to that from non-tumor control mice. Oxidation, nitrosylation 
and depletion of the calstabin1 stabilizing subunit are consid-
ered a biochemical signature for leaky RYR1[17,24]. To determine 
whether the RyR1 modifications observed in the mouse models 
of bone metastases are relevant to human cancer, we examined 
skeletal muscle samples from patients with breast and lung can-
cer–associated bone metastases for RyR1 and compared them to 
those from humans who did not have cancer and found the same 
post-translational modifications as we observed in the murine 
models, which we hereafter refer to as the biochemical signature 
of leaky RyR1 channels.
Inhibiting RyR1 Ca2+ leak improves muscle strength
 S107 is a small molecule in the 1,4-benzothizepine 
family. It inhibits the oxidation-induced depletion of the chan-
nel-stabilizing subunit calstabin1 from the RyR1 complex. This 
action stabilizes the closed state of the channel and prevents ab-
errant intracellular Ca2+ leak, thereby improving the Ca2+ sig-
nal for muscle force production and enhancing muscle strength 
and exercise capacity in rodents[25]. Significant improvement in 
forelimb grip strength and ex vivo muscle-specific force of the 
EDL in mice with breast cancer–associated bone metastases was 
achieved when mice were treated with S107 compared to vehi-
cle-treated mice. In mice with bone metastases, S107 treatment 
prevented depletion of calstabin1 from the skeletal muscle RyR1 
complex but, as previously reported, did not prevent oxidation 
or nitrosylation of RyR1[26]. In Mice with bone metastases, S107 
treatment also led to higher peak tetanic Ca2+ in muscle fibers 
and lower skeletal muscle RyR1 open probability (Po), which 
is consistent with decreased SR Ca2+ leak, compared to vehicle 
treated mice.      
 The SR/ER membrane is endowed with Ca2+ release 
channels and SERCA pumps. Ca2+ release channels (RYR1) al-
low Ca2+ to diffuse out of the store on opening of the channels 
whereas the SERCA accumulate Ca2+ in the lumen against its 
electrochemical gradient[27] and lower SERCA activity could 
contribute to decreased tetanic Ca2+.  In our studies, we observed 
no difference in SERCA activity in skeletal muscle from non-tu-
mor mice as compared to that from mice with bone metastases 
whether or not mice were treated with S107. 
 To see if S107 treatment had any effect on tumor 
growth in mice, we looked by x-ray at the extend of bone de-
struction and histologically on tumor burden as well as number 
of osteoclasts at the tumor bone interface as markers of tumor 
aggression and development. S107 had no effect on the develop-
ment and progression of bone metastases in our mouse model. 
S107 has no effect on body weight, or the distribution of fat and 
lean composition, muscle mass or affect muscle fiber diameter 
or mid-calf cross-sectional area as compared to vehicle-treat-
ed mice. S107 treatment did eliminate the correlation between 
higher bone destruction and lower muscle function.
TGF-β inhibition improves muscle strength
 As mentioned earlier, TGF-β stimulates tumor pro-
duction of osteolytic factors that stimulate further bone resorp-
tion[8,9]. Our data showed that TGF-β–induced phosphorylation 
4of the signaling factor SMAD3 was higher in skeletal muscle 
from mice bearing MDA-MB-231 breast cancer bone metasta-
ses compared to in non-tumor control mice. This was not ob-
served in mice bearing MDA-MB-231 primary breast cancer 
tumor without bone metastases. This observation is consistent 
with a systemic effect of bone-derived TGF-β on skeletal mus-
cle. SMAD3 phosphorylation was also higher in skeletal muscle 
from patients with breast and lung cancer bone metastases than 
in skeletal muscle from patients without bone metastases. TGF-β 
released from the sites of bone destruction and circulate in the 
blood, measurements of serum TGF-β concentrations was high-
er in tumor-bearing mice with bone metastases, but not in those 
with primary breast cancer compared to non-tumor mice. Higher 
SMAD3 phosphorylation was also confirmed in skeletal muscle 
samples from mouse models of human cancers with osteolytic 
or mixed osteolytic/osteoblastic bone metastases due to A549 
and RWGT2 lung cancer, MCF-7 breast cancer, PC-3 prostate 
cancer, and JJN-3 multiple myeloma compared to non-tumor 
controls.In contrast, the osteoblastic ZR75-1 breast cancer bone 
metastases did not exhibit higher SMAD3 phosphorylation in 
skeletal muscle compared to non-tumor control mice.
 TGF-β released as a consequence of osteolytic bone 
destruction was determined to play a role in cancer-associated 
muscle weakness when TGF-β release from bone was inhabited 
using various pharmacological agents. Using TGF-β receptor I 
kinase inhibitor SD-208, anti-resorptive bisphosphonate therapy 
or combination of the two drugs,in mouse model of breast cancer 
bone metastases, to reduce TGF-β release from the bone matrix 
had a significant reduction in SMAD3 phosphorylation, indicat-
ing a block to TGF-β signaling and improved muscle function as 
indicated by significant improvement in forelimb grip strength 
and EDL muscle specific force. Treatment also reduced RyR1 
oxidation and nitrosylation and preserved calstabin1 binding to 
the RyR1 complex compared with vehicle-treated mice. In vitro, 
SD-208 reduced SMAD3 phosphorylation in C2C12 myotubes 
treated with TGF-β. These data suggest that bone-derived TGF-β 
plays a critical role in cancer-associated muscle weakness.
RyR1 oxidation in response to TGF-β is mediated by NA-
DPH oxidase 4 (Nox4)
 The mechanism by which TGF-β mediates oxidation 
of RyR1 was shown to be through Nox4. Nox4 is expressed in 
skeletal muscle and contributes to oxidative stress in cardio-
myocytes and Nox4 protein is increased in muscle in response 
to TGF-β signaling[28,29]. Previously published data show that 
Nox4 protein interacts with RyR1 channels[30]. Our current data 
demonstrated an increase in Nox4 co-immuno precipitation with 
RyR1 in skeletal muscle from mice with bone metastases as well 
as in muscle samples from patients with breast and lung cancer 
bone metastases. This observation of an increase in Nox4-RyR1 
binding was reported in bone metastases from mouse model of 
breast cancer (MDA-MB-231, MCF-7), prostate cancer (PC-3), 
lung cancer (RWGT2 and A549), and multiple myeloma (JJN-
3). No increase in Nox4-RyR1 binding in muscle from mice with 
MDA-MB-231 primary breast cancer without bone metastases 
was observed and no increase Nox4-RyR1 binding was reported 
in bone metastases from breast cancer osteoblastic line ZR-75-1.
 In-vitro studies demonstrated that TGF-β treatment 
increased Nox4 protein expression in myotubes. This observed 
increase in Nox4 protein expression was blocked using TGF-β 
RI kinase inhibitor, SD208, but not S107. When myotubes were 
treated with TGF-β Nox4 binding to RyR1 channels was in-
creased.  When we knocked down Nox4 in myotubes TGF-β 
treatment did not induce RyR1 is remodeling or reduction of 
calstabin1 binding to RyR1 compared to scrambled control sam-
ples. This data definitely shows that Nox4 mediates TGF-β in-
duced oxidation of RyR1.
Summary
 Despite the fact that many important advances have 
occurred in the field of cancer cachexia over the past decade, 
including progress in understanding the mechanisms of cancer 
and the development of promising pharmacologic drugs, no 
approved agents for cancer cachexia currently exist. Cachexia, 
weight loss and muscle weakness are associated with important 
clinical outcomes such as decreased survival, fewer completed 
cycles of chemotherapy, more treatment side effects, and poorer 
health-related quality of life.
Figure 2: TGF-β released from bone as a result of bone destruction by 
osteoclast that is stimulated by cancer cell. TGF-β drives the expression 
of Nox4 in muscle through Smad2/3 signaling and Nox4 produce reac-
tive oxygen species (ROS) which cause oxydation of the RYR1 on the 
Sarcoplasmic Reticulum (SR). Oxidation of RYR1 leads of binding of 
the RYR1 stabilizing unit (calstabin1) which leads to Ca2+ leak from the 
SR. Thus depleting the Ca2+ store and causes reduction in muscle force.
 Different type of cancer including breast, prostate, lung 
and multiple myeloma shows evidence for the role of the tu-
mor-bone microenvironment in the generation of muscle weak-
ness. This observation suggests that a common mechanism may 
be broadly applicable to different types of cancer that tend to 
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metastasize to bone or other disease states associated with bone 
loss. Our observations suggest that different types of therapy in-
cluding blocking TGF-β using TGFBRI kinase inhibitor or by 
antiresorptive drugs (bisphosphonates or denosumab) or block-
ing RYR1 calcium leak can all lead to improvement in muscle 
strength associated with cancer. It is now evident that a link has 
been established between bone and skeletal muscle whereby fac-
tors elaborated from bone can profoundly affect muscle function 
(Figure 2).
 Thus, targeting skeletal muscle weakness caused by 
the TGF-β–Nox4–RyR1 axis represents a novel therapeutic ap-
proach to improving the quality of life in cancer patients with 
muscle weakness associated with increased bone destruction. 
Our observations indicate that muscle dysfunction can occur 
before the loss of muscle mass (as seen with cachexia) and sug-
gest that a spectrum of muscle dysfunction, ranging from muscle 
weakness to profound cachexia, exists in patients with bone me-
tastases.
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